A MESSAGE TO OUR CUSTOMERS AND COLLEAGUES
TriLink BioTechnologies is continuously monitoring and assessing the current situation with respect to the coronavirus (COVID-19) outbreak and responding appropriately as it evolves.
As COVID-19 continues to impact our communities, we are mindful that there may be concerns regarding ordering and general delays. Our commitment is to remain in operation in order to supply mission-critical products to our customers, who are in turn developing life-saving medications and diagnostic tests. We have an active Business Continuity Plan in place and a specific response plan to the COVID-19 situation.
Currently, our manufacturing partnerships are fueling development of COVID-19 diagnostic test kits and vaccines by providing high-quality and efficient delivery of mRNA, capping reagents, oligonucleotides, and NTPs. We provide critical reagents that are making an immediate impact in global health and safety, and we are doing everything in our power to maintain business as usual. As of today, we are currently experiencing no business interruption and our facility remains open and operational.
Impact to Manufacturing:
Our manufacturing and support teams continue to be fully operational. We are maintaining tight communication and are working closely with our suppliers to ensure uninterrupted manufacturing workflows. We have conducted a risk assessment of our supply chain, resources and facilities and they are all secure with contingencies in place. Within our manufacturing facility, we are following the guidelines of local and national health organizations in order to mitigate the spread of COVID-19.
Impact to Business Operations:
TriLink BioTechnologies is taking all recommended precautions to ensure we keep our employees and their families safe, while maintaining our business continuity in support of our customers. Our customer service and order fulfillment teams continue to operate to ensure that all customer orders are processed promptly and that we continue to meet our customers’ expectations. Worksite recommendations by WHO, CDC, and local and national authorities are being implemented, including:
- Releasing all non-site essential employees to work remotely from home
- Having our customer service and sales teams work remotely to continue to provide expert consultative and technical support through our existing phone lines or via email
- Hosting virtual alternatives to meetings and conferences
- Implementing a highly restrictive travel policy
- Heightening hygiene protocols
- Practicing social distancing, including prohibiting guests from entering our facility
You may also call us at +1 (800) 863-6801, +1 (888) 931-6320 or +1 (858) 546-0004.